Prevalence and Main Features of Chronic Refractory Cough.

NCT ID: NCT04078542

Last Updated: 2019-09-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cough is among the most common causes of medical consultation in primary care.\[1\] Chronic cough, arbitrarily defined as symptom persisting more than 8 weeks, has been variably reported in different settings and geographical area, with an overall prevalence of 10-20% in the general population, that increases up to 40-50% in pneumology specialist clinics.\[2,3\] While acute cough is generally caused by the common cold and typically lasts one to three weeks, chronic persisting cough can underlie more serious disease processes. Moreover, it can impair quality of life,\[4\] possibly leading to tiredness, urinary incontinence, and eventually syncope. It also has psychosocial effects such as embarrassment and negative impact on social interactions.

A careful clinical history may provide important diagnostic clues that allow therapeutic trials without the need of further investigations.\[5\] Smoking history, medication list and presence and character of sputum should be carefully detailed. Identification of the causes of productive cough is generally straightforward and strategies for intervention and treatment are well defined.\[5\] Conversely, chronic dry or poorly productive cough represents a greater diagnostic challenge. Several studies have shown that in nonsmokers with normal chest radiography who are not taking ACE-inhibitor, chronic cough is usually due to asthma, rhinosinusitis or gastro-esophageal reflux (GER).\[6\] Many dedicated algorithms have been identified to guide the diagnostic phase and to sequentially coordinate the execution of further diagnostic deepening and/or empirical treatments, based on cost-effectiveness principles.\[5,7-9\] Among these, the European Respiratory Society (ERS) recommendations\[5\] are widely applied in clinical practice and broadly parallel those released by the American College of Chest Physicians\[7\]. This notwithstanding, a proportion of cases do not reach a definite diagnosis and resolutive treatment\[7\]. This condition is termed chronic refractory cough (CRC), chronic idiopathic cough, or unexplained chronic cough.\[7,10\] It can be diagnosed when patients have no identified causes of chronic cough (unexplained or idiopathic chronic cough) or when the cough persists after investigation and treatment of cough-related conditions. Because patients with unexplained chronic cough often receive specific therapies, such as inhaled corticosteroids or proton pump inhibitors, they can also be classified as having CRC.

The real prevalence of CRC is not well-know and many cases of CRC may be actually misdiagnoses due an incomplete application of recommended work-up. In the present study we aim to estimate the prevalence of chronic cough in different care settings, together with the prevalence of CRC according to a systematic and integrated approach. The careful application of the recommendation defined by ERS guidelines will allow to detect truly refractory cases of chronic cough.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic cough

Subject complaining cough from at least 8 weeks

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* complaining chronic cough (lasting more than 8 weeks)

Exclusion Criteria

* Unwilling to participate
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Campus Bio-Medico University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raffaele Antonelli Incalzi

Full Professor of Internal Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raffaele Antonelli Incalzi, MD

Role: PRINCIPAL_INVESTIGATOR

Campus Bio Medico

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Campus Bio-Medico di Roma

Roma, , Italy

Site Status

IRCCS Maugeri Tradate

Roma, , Italy

Site Status

Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore

Roma, , Italy

Site Status

Policlinico Universitario Agostino Gemelli Università Cattolica del Sacro Cuore

Roma, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Antonio De Vincentis, MD

Role: CONTACT

06225411445

Antonio De Vincentis, MD

Role: CONTACT

062254114445

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Antonio De Vincentis, MD

Role: primary

2254114445 ext. 06

Antonio Spanevello

Role: primary

331829111

Luca Richeldi

Role: primary

30151 ext. 06

Roberto Bernabei

Role: primary

30151 ext. 06

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ComEtx

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.